Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myeloid Malignancies
Open-data reference.
6 US clinical trials · 4 currently recruiting
Active & Recent Trials
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
M.D. Anderson Cancer Center
NCT06383572
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
M.D. Anderson Cancer Center
NCT06930651
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Franziska Wachter
NCT05796570
A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies
M.D. Anderson Cancer Center
NCT06668584
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
Geron Corporation
NCT01731951
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
M.D. Anderson Cancer Center
NCT05115630
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 2 |
| Phase 2 | 4 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Myeloid Malignancies Trial Landscape
ClinicalTrials.gov lists 6 US studies indexed under Myeloid Malignancies, and 4 of those are currently open to recruitment — roughly 67% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Myeloid Malignancies shows 0 late-stage studies (Phase 3 and Phase 4 combined) alongside 6 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Myeloid Malignancies is led by M.D. Anderson Cancer Center with 4 indexed trials, alongside 2 other organizations in the top contributor list. The list on this page surfaces up to 6 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Myeloid Malignancies?
PlainTrial tracks 6 US clinical trials for Myeloid Malignancies, of which 4 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Myeloid Malignancies?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.